Preclinical studies have demonstrated that inhibiting neutral ceramidase can prevent the occurrence and progression of colon cancer (Garcia-Barros et al., 2016), whereas inhibiting acid ceramidase can inhibit the proliferation of non-small-cell lung cancer and enhance its sensitivity to cisplatin (Yildiz-Ozer et al., 2018; White-Gilbertson et al., 2019). This evidence concerns the gene ASAH2 and colonic neoplasm.